Imohgen Alo rang the bell at John Hunter Children's Hospital on Friday to mark the end of her cancer treatment. The NSW Lake ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

What started out as shoulder pain turned into a living nightmare for a Melbourne girl and her family after doctors discovered a large mass in the eight-year-old’s chest, which turned out to be a rare ...

Phothera, the leading manufacturer of FDA-cleared light therapy devices for chronic skin conditions including vitiligo, psoriasis, atopic dermatitis, and cutaneous T-cell lymphoma (CTCL), today ...

After weeks of doctor visits and her condition worsening, Emma Operacz was given an unexpected diagnosis ...

Kathmandu, March 7 -- Nepal has approved its first domestically manufactured CAR T-cell therapy for clinical use, marking a milestone in the country's cancer treatment capabilities. The Department of ...

Lyell Immunopharma, Inc. ( LYEL) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM EST ...

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator GNTbm-38, with global rights for cancer ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032, registering a CAGR of 7.47% during 2024--2032. Growth is underpinned by ...